The medtech market’s fast growth and unfettered demand attracts investment groups, while hospital suppliers consolidate.
The recent disappointing sales of drug-coated devices for peripheral arterial disease look likely to become the norm.
A poor quarter is followed by an acquisition, but is it big enough?
Transvaginal mesh implants are banned in the US, but remain a possibility in Europe.
The battle for dominance of the transcatheter aortic valve market has shifted to new territory. And once again, Edwards Lifesciences is winning.
Transcatheter mitral valve replacement is wrenching the spotlight away from the repair devices that grabbed the headlines last summer.
The immensely complex and long-running intertwined litigation between the two medtechs has been brought to an end.
Some medtech stocks did decline in 2018, but many more increased in value.
Vantage’s roundup of medtech news you might have missed includes Boston Scientific hitting its 11th biz dev deal of the year.